Clinical Research Directory
Browse clinical research sites, groups, and studies.
Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy
Sponsor: Trisha Wise-Draper
Summary
The purpose of this research study is to test the safety and efficacy of nivolumab after salvage resection in head and neck cancer in patients that have previously received definitive radiation with or without chemotherapy.
Official title: A Single Arm Phase 2 Study of Adjuvant Nivolumab After Salvage Resection in Head and Neck Squamous Cell Carcinoma Patients Previously Treated With Definitive Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
39
Start Date
2017-12-06
Completion Date
2024-07
Last Updated
2024-02-28
Healthy Volunteers
No
Conditions
Interventions
Nivolumab
Nivolumab 480 mg IV infusion
Locations (2)
Karmanos Cancer Institute
Detroit, Michigan, United States
UC Health
Cincinnati, Ohio, United States